Your browser doesn't support javascript.
loading
Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.
Irimia, Adriana; Serra, Andreia M; Sarkar, Anita; Jacak, Ronald; Kalyuzhniy, Oleksandr; Sok, Devin; Saye-Francisco, Karen L; Schiffner, Torben; Tingle, Ryan; Kubitz, Michael; Adachi, Yumiko; Stanfield, Robyn L; Deller, Marc C; Burton, Dennis R; Schief, William R; Wilson, Ian A.
Afiliación
  • Irimia A; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Serra AM; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
  • Sarkar A; Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America.
  • Jacak R; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America.
  • Kalyuzhniy O; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
  • Sok D; Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America.
  • Saye-Francisco KL; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America.
  • Schiffner T; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Tingle R; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
  • Kubitz M; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
  • Adachi Y; Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America.
  • Stanfield RL; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America.
  • Deller MC; International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
  • Burton DR; Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, United States of America.
  • Schief WR; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America.
  • Wilson IA; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
PLoS Pathog ; 13(2): e1006212, 2017 02.
Article en En | MEDLINE | ID: mdl-28225819
ABSTRACT
Among broadly neutralizing antibodies to HIV, 10E8 exhibits greater neutralizing breadth than most. Consequently, this antibody is the focus of prophylactic/therapeutic development. The 10E8 epitope has been identified as the conserved membrane proximal external region (MPER) of gp41 subunit of the envelope (Env) viral glycoprotein and is a major vaccine target. However, the MPER is proximal to the viral membrane and may be laterally inserted into the membrane in the Env prefusion form. Nevertheless, 10E8 has not been reported to have significant lipid-binding reactivity. Here we report x-ray structures of lipid complexes with 10E8 and a scaffolded MPER construct and mutagenesis studies that provide evidence that the 10E8 epitope is composed of both MPER and lipid. 10E8 engages lipids through a specific lipid head group interaction site and a basic and polar surface on the light chain. In the model that we constructed, the MPER would then be essentially perpendicular to the virion membrane during 10E8 neutralization of HIV-1. As the viral membrane likely also plays a role in selecting for the germline antibody as well as size and residue composition of MPER antibody complementarity determining regions, the identification of lipid interaction sites and the MPER orientation with regard to the viral membrane surface during 10E8 engagement can be of great utility for immunogen and therapeutic design.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / VIH-1 / Anticuerpos Neutralizantes Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / VIH-1 / Anticuerpos Neutralizantes Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos